# GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer

> **NCT02983604** · PHASE1,PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 14 (actual)

## Conditions studied

- Advanced Estrogen Receptor Positive HER2- Breast Cancer

## Interventions

- **DRUG:** GS-5829
- **DRUG:** Exemestane
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT02983604
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01-10
- **Primary completion:** 2018-07-19
- **Final completion:** 2018-07-19
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2019-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02983604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02983604, "GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02983604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*